The Center for PharmacoEconomics Research (CPER) is a research institute specialized in pharmacoeconomics research and assessment. It aims to be an independent organization recognized and trusted by regulators, medical experts, health care providers and the wider public in China. With the deepening of China’s medical and health care reforms, pharmacoeconomics is playing an increasingly important role in public health policy decision-making, new drug approval, essential drug listing, pricing and reimbursement, healthcare access improvements, and healthcare expenditure management. CPER is an independent organization that will conduct pharmacoeconomics research, promote use of health technology appraisals, facilitate international cooperation, and support implementation of evidence-based public health policies in China. CPER is affiliated to the China Journal of Pharmaceutical Economics, the first academic journal in China dedicated to pharmacoeconomic research. CPER vision and mission Our vision is: • To become a leading think tank in pharmacoeconomics research in China and to engage with government institutions, the medical and pharmaceutical industry and the wider public in order to promote the understanding and application of pharmacoeconomics research. • To become an independent organization in clinical and economic evaluations recognized and trusted by all stakeholders in the health technology assessment process. Our mission is: • To assist in development of research capabilities in pharmacoeconomics and evidence-based medicine in China. • To facilitate the establishment of a health technology assessment program that is practical and beneficial to China’s healthcare system. • To support the creation and implementation of evidence-based market access policies in China.